NEUP Neuphoria Therapeutics Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1191070 · Fiscal year ends 06/30
Financial factors as of 2026-09-30 (2027Q1), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY47.5%
TTM EPS YoY127.1%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-27.6%
ROA-18.3%
ROIC (approx.)-568.0%
Asset turnover—
Leverage & solvency
Liabilities / assets13.4%
Debt / equity0.00x
Current ratio18.05x
Interest coverage—
Cash quality & payout
Operating cash flow / net income1.95x
Accruals ratio17.3%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20262026-06-30 · USD | FY20252025-06-30 · USD | FY20242024-06-30 · USD | FY20232023-06-30 · USD | FY20222022-06-30 · AUD |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $1.17M | $15.65M | — | 22,047AUD | 263,634 |
| R&D expense | — | $9.01M | $9.42M | $13.07M | 16.00M |
| SG&A expense | $7.44M | $7.77M | $8.47M | $8.91M | — |
| Operating income | -$16.45M | -$1.13M | -$17.89M | -$21.98M | — |
| Interest expense | — | — | — | 29,230AUD | 44,165 |
| Pretax income | -$13.59M | -$837,998 | -$15.58M | -$21.52M | -21.95M |
| Income tax | -$139,173 | -$468,366 | -$87,320 | -$139,174 | -191,808 |
| Net income | -$13.45M | -$369,632 | -$15.49M | -$21.38M | 913,373 |
| EBITDA | -$15.79M | -$466,201 | -$17.23M | -$21.32M | — |
| EPS (basic) | -3.06 | -0.23 | -18.62 | -0.02 | -0.02 |
| EPS (diluted) | -3.06 | -0.23 | -18.62 | -0.02 | -0.02 |
| Weighted avg. shares (diluted) | 4.40M | 1.62M | 832,225 | 1.47B | 1.35B |
| Balance sheet | |||||
| Cash & equivalents | $19.87M | $14.29M | $12.69M | $12.18M | 33.56M |
| Receivables | $813,431 | $11,948 | $126,884 | $426,087 | 64,360 |
| Current assets | $21.07M | $15.04M | $13.19M | $13.33M | 41.81M |
| PP&E, net | — | $2,771 | $1,994 | $2,522 | 5,172 |
| Goodwill | $3.50M | $8.64M | $8.69M | $8.69M | 12.87M |
| Intangibles | $4.14M | $4.80M | $5.47M | $6.13M | 9.84M |
| Total assets | $28.71M | $28.59M | $27.65M | $28.56M | 65.31M |
| Current liabilities | $756,581 | $4.22M | $3.83M | $2.74M | 3.36M |
| Total liabilities | $4.11M | $9.59M | $10.16M | $6.55M | 8.40M |
| Shareholders' equity | $24.60M | $19.00M | $24.60M | $22.01M | $39.23MUSD |
| Shares outstanding | 5.41M | 1.98M | 1.10M | 1.47B | — |
| Cash flow statement | |||||
| Operating cash flow | -$12.35M | $77,229 | -$14.68M | -$14.64M | -21.76M |
| Capital expenditure | — | — | — | — | 1,544 |
| Free cash flow | — | — | — | — | -21.76M |
| Investing cash flow | — | — | — | 479,528AUD | 621,703 |
| Financing cash flow | $17.92M | $1.53M | $15.11M | $3.86M | 27.00M |
| Depreciation & amortization | $662,955 | $662,890 | $662,991 | $663,192 | 1.11M |
| Stock-based compensation | $351,600 | $163,772 | $814,808 | $1.35M | 2.83M |
Free plan shows the latest 5 periods; Pro shows all 7 🔒
· This company uses different currencies across periods or line items (e.g. USD convenience translations in annual reports). Each column header shows its currency and cells in a different currency are marked; do not compare figures across currencies. Charts use only periods in the latest period's currency.
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.